Enfortumab Vedotin-ejfv (Solution) provides a Nectin-4-targeting antibody-drug conjugate (ADC) for cancer and oncology research and specifically combines a Nectin-4-directed monoclonal antibody with monomethyl auristatin E (MMAE), supporting studies of targeted cytotoxicity and ADC mechanisms.
Key Features and Benefits
- Nectin-4-Targeting ADC: Combines a Nectin-4-directed monoclonal antibody with the cytotoxic payload MMAE.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule-disrupting agent specifically used in ADC research.
- Nectin-4 Recognition: Supports investigation of Nectin-4 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable linker specifically designed to facilitate intracellular release of MMAE after cellular uptake.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAE delivery to Nectin-4-expressing cancer cells.
- Microtubule Disruption: MMAE inhibits microtubule dynamics, specifically supporting studies of ADC-mediated cytotoxic mechanisms.
- Solution Format: Provides Enfortumab Vedotin-ejfv in solution form for convenient experimental use and assay preparation.
Applications
- Nectin-4-Positive Cancer Research: Supports studies involving tumors that express the Nectin-4 cell-surface protein.
- Bladder Cancer Research: Useful for investigating Nectin-4-targeted strategies in urothelial and bladder cancer models.
- ADC Research: Supports studies of antibody targeting, internalization, payload delivery, and cytotoxic activity.
- Targeted Cancer Research: Useful for investigating antibody-mediated delivery of MMAE to cancer cells.
- Cell-Based Cancer Assays: Supports evaluation of binding, internalization, cytotoxic response, and target-dependent activity.
- Mechanism-of-Action Studies: Supports investigation of Nectin-4 targeting and MMAE-mediated microtubule disruption.
- Comparative ADC Research: Useful for comparing ADC targeting strategies, linkers, payloads, and cellular responses.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Enfortumab Vedotin-ejfv (Solution) combines Nectin-4-directed targeting with an MMAE payload and specifically supports bladder cancer, Nectin-4, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
